54% migraine day reduction across 12 weeks
(4.2 fewer monthly migraine days from 7.8 baseline) vs 33% (2.5 fewer monthly migraine days from 7.5 baseline) with placebo1
QULIPTA 60 mg (n=222); placebo (n=214); P<0.001
Primary endpoint: Mean monthly migraine day (MMD) reduction across 12 weeks
REDUCTIONS OBSERVED AS EARLY AS3,4:
Additional endpoints
DAY 1
AFTER THE FIRST DOSE†‡


51%
LESS LIKELY TO HAVE A MIGRAINE ATTACK COMPARED WITH PLACEBO
Week 1
Significant reduction‡§


53%
Migraine day reductioN n=216
Placebo
15% n=211


The majority of impact occurred within Weeks 1-4.3
*Data from Phase 3 ADVANCE trial.
†Day 1 data: 12.3% (26/211) of QULIPTA 60 mg patients had a migraine day vs 25.2% (51/202) of placebo patients.3
‡Week 1 QULIPTA 60 mg: Baseline MMD was 1.93; change from baseline: -1.03. Week 1 placebo: Baseline MMD was 1.88; change from baseline: -0.29.3
Primary Endpoint:
> QULIPTA 30 mg: 3.9 fewer monthly migraine days across 12 weeks (baseline MMD was 7.9) (n=223) (P<0.001)1
> QULIPTA 10 mg: 3.7 fewer monthly migraine days across 12 weeks (baseline MMD was 7.5) (n=214) (P<0.001)1
Limitation
The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity. Results could represent chance findings. Data should be interpreted with these factors in mind.
CONTINUOUS MIGRAINE PREVENTIVE POWER
Reductions continued across 12 weeks1



BASELINE MMD WAS, ON AVERAGE, 7.7.1
MANY PATIENTS ACHIEVED A 50% TO 100% REDUCTION IN MONTHLY MIGRAINE DAYS WITH QULIPTA 60 mg1,3
50%-100% RESPONSE RATE
Secondary endpoint: Percentage of patients who achieved ≥50% MMD reduction across 12 weeks1,2
Additional endpoint: Percentage of patients who achieved ≥50% MMD reduction in Weeks 1-4, 5-8, 9-123,4



Limitation
The analyses of additional endpoints were not tested in hierarchical order or adjusted for multiplicity. Results could represent chance findings. Data should be interpreted with these factors in mind.
*Data from the Phase 3 ADVANCE trial.
SEE THE SAFETY
PROFILE OF QULIPTA